{"filings":[{"id":1388126,"accession_number":"0001193125-26-292567","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-07-01T20:15:31+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio director Andrew Levin resigns; Breanna O'Reilly elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Levin resigned from the board effective June 29, 2026.","Breanna O'Reilly, Ph.D., elected as director effective June 29, 2026.","O'Reilly received option for 70,284 shares at $13.36, vesting over 3 years.","O'Reilly to receive $40,000 annual cash retainer and annual equity grants.","No family relationships or related-party transactions with O'Reilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1028476,"accession_number":"0001193125-26-269567","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-06-12T20:36:30+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Climb Bio enters $100M ATM equity facility with Jefferies, terminates prior Oppenheimer agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters $100M at-the-market equity distribution agreement with Jefferies LLC for common stock sales.","Jefferies will receive up to 3.0% of gross sales price per share; proceeds to fund general corporate purposes.","Terminates prior $22.35M ATM facility with Oppenheimer & Co.; no shares were sold, no penalties incurred.","Shares sold from time to time on Nasdaq Global Market at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982036,"accession_number":"0001193125-26-266688","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-06-11T11:12:53+00:00","items":["8.01"],"status":"ready","headline":"Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.","Budoprutug was well tolerated with no serious adverse events, no discontinuations, and all AEs Grade 1-2.","In 250 mg cohort, B-cells depleted by >90% at Week 4; mean platelet count increased by 111,000/µL at Week 24.","Four of six patients achieved durable platelet responses; two had platelet levels ≥100x10^3/µL for over 24 weeks.","Of four patients previously treated with rituximab, three responded to budoprutug, two with durable/complete responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918196,"accession_number":"0001193125-26-261716","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-06-08T20:07:47+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Climb Bio stockholders elect Cumbo and Williams; reject charter amendment; approve equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alexander (Bo) Cumbo elected to Board with 26,035,689 votes for; Douglas Williams with 24,505,866 votes for.","Ratification of PricewaterhouseCoopers as FY2026 auditor: 35,206,304 for, 63,633 against, 2,552 abstain.","Charter amendment for 'cause' removal of directors failed: 27,299,535 for, 130,187 against, 7,841,185 broker non-votes.","2021 Equity Incentive Plan amendment approved: 19,604,493 for, 7,810,582 against, 7,841,185 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":870276,"accession_number":"0001193125-26-258372","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-06-05T11:12:49+00:00","items":["8.01"],"status":"ready","headline":"Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.","Preliminary safety from 49 healthy volunteers (single doses up to 320 mg): no SAEs, DLTs, or discontinuations; all AEs mild-moderate and transient.","Partner Mabworks to initiate Phase 2 dosing in IgAN patients in Q3 2026 in China.","Company plans to advance CLYM116 into further clinical development based on data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95303,"accession_number":"0001193125-26-210295","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.","Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.","Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.","Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.","CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95302,"accession_number":"0001193125-26-205079","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.","Fast Track Designation received for primary membranous nephropathy (pMN).","Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.","Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.","Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95301,"accession_number":"0001193125-26-183711","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Climb Bio raises $110M in private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.","Closing expected April 29; participants include RA Capital, Adage Capital, Cormorant, and others.","Proceeds to fund late-stage development of budoprutug and CLYM116 for immune-mediated diseases.","Company to file resale registration statement within 45 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95300,"accession_number":"0001193125-26-142114","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio SVP Finance to depart April 30; CFO adds principal accounting officer role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cindy Driscoll, SVP Finance and principal accounting officer, to separate from Climb Bio effective April 30, 2026, by mutual agreement.","CFO Susan Altschuller will also serve as principal accounting officer starting on the Separation Date.","Altschuller has been CFO since Oct 2025; prior CFO roles at Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108255,"accession_number":"0001193125-26-092520","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.","FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.","Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.","Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.","CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108254,"accession_number":"0001193125-26-006994","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).","Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).","Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).","Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).","Cash, cash equivalents, and marketable securities expected to fund operations into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124697,"accession_number":"0001193125-25-338318","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.","Alumis invoiced $3M milestone payment due Jan 1, 2026 for Phase 2 initiation; Climb denies any obligation.","Climb dosed first patient in Phase 2 trial on Nov 17, 2025; claims no Royalty-Bearing Patents exist to trigger milestone.","Dispute centers on interpretation of APA; Climb argues no patents transferred or filed within nine months of closing.","Climb states it attempted to resolve out of court but Alumis refused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124696,"accession_number":"0001193125-25-315108","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Climb Bio exchanges 20.44M shares for pre-funded warrants; RA Capital voting capped at 33%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 20,440,000 shares for pre-funded warrants with $0.0001 exercise price via Section 3(a)(9) exemption.","Post-exchange shares outstanding: 47,744,435; RA Capital to own ~23% voting power.","RA Capital and affiliates agree to vote any holdings above 33% proportionally with other stockholders.","RA Capital may exchange additional shares for warrants with company's written consent.","Pre-funded warrants are exercisable immediately and include a 33% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124695,"accession_number":"0001193125-25-268075","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.","R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.","Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.","CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.","New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124694,"accession_number":"0001193125-25-241951","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.","Three of four patients required no further immunosuppressive treatment after up to 4 doses.","No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).","Data support continued development of budoprutug for B-cell mediated diseases.","Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124693,"accession_number":"0001193125-25-227025","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Climb Bio appoints Susan Altschuller as CFO, grants 600,000 stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Susan Altschuller, Ph.D., MBA, as CFO and Treasurer effective Oct 1, 2025; previously CFO at Cerevel and ImmunoGen.","Base salary $510,000/year; eligible for annual bonus up to 40% of base.","Received option to purchase 600,000 shares under 2025 Inducement Plan; vesting 25% on one-year anniversary then monthly.","Board amended Inducement Plan to increase reserved shares from 1.25M to 2.0M.","Cindy Driscoll steps down as principal financial officer but continues as principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141385,"accession_number":"0001193125-25-221756","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.","Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.","CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.","CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.","Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141384,"accession_number":"0000950170-25-106913","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.","R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.","Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.","CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.","Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159203,"accession_number":"0001193125-25-142359","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio appoints Cindy Driscoll as Principal Financial Officer; Emily Pimblett resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Cindy Driscoll as SVP Finance, principal financial officer and principal accounting officer effective June 17, 2025.","Driscoll receives $355k base salary, 35% target bonus, and 200,000-share stock option under 2025 Inducement Plan.","Emily Pimblett resigns as SVP Finance and Chief Accounting Officer, effective June 30, 2025.","CEO Aoife Brennan ceases interim principal financial officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159202,"accession_number":"0001193125-25-135864","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Climb Bio shareholders elect two directors, ratify PwC as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Judith Dunn, Ph.D. elected with 36,827,909 votes for, 6,615,228 withheld, 10,126,633 broker non-votes.","Stephen Thomas, Ph.D. elected with 41,359,959 for, 2,083,178 withheld, same broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor: 53,442,396 for, 8,780 against, 118,594 abstentions.","Both directors will serve three-year terms expiring at 2028 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159201,"accession_number":"0001193125-25-125866","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.","Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.","CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.","No changes to Brennan's compensation or arrangements in connection with this appointment.","Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159200,"accession_number":"0000950170-25-070901","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio Q1 cash $197.8M; pipeline on track for 2025 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities $197.8M; expected to fund operations through 2027.","R&D expense $17.3M including $9.0M upfront to Mabworks for CLYM116 license.","Budoprutug Phase 2 pMN FDA-cleared; ITP and SLE trials on track for H1 2025 initiation.","CLYM116 IND/CTA submission expected H2 2025 with preclinical data in H2.","Appointed Kim Drapkin and Bo Cumbo as independent directors; Perrin Wilson as CBO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159199,"accession_number":"0001193125-25-069668","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio announces board changes: two directors depart, two new directors elected","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Tate resigned as director on March 27, 2025, also leaving audit and nominating committees; no disagreement.","Adam Rosenberg will not seek re-election at 2025 annual meeting; no disagreement with company.","Board expanded from 7 to 8; Alexander (Bo) Cumbo and Kimberlee Drapkin elected effective March 28, 2025.","Cumbo to chair compensation committee; Drapkin to chair audit committee.","Each new director received option to purchase 80,000 shares at $1.28/share, vesting over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177650,"accession_number":"0001193125-25-062629","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Climb Bio reports Q4/FY2024 results, cash $212.5M through 2027; launches $22.35M ATM offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Entered ATM equity offering of up to $22.35M via Oppenheimer; 3% commission; proceeds to support pipeline.","Cash, equivalents and marketable securities $212.5M at year-end; expected to fund operations through 2027.","Net loss $73.9M for FY2024 includes $51.7M in-process R&D from Tenet acquisition; Q4 net loss $8.4M.","FDA cleared Phase 2 trial for budoprutug in pMN and Phase 1b/2a in ITP; dosing starts H1/H2 2025.","In-licensed CLYM116 (anti-APRIL) for IgAN; IND-enabling; preclinical data H2 2025; new CBO Perrin Wilson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177649,"accession_number":"0001193125-25-004129","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","2.02","8.01"],"status":"ready","headline":"Climb Bio licenses MIL116 antibodies from Mabworks; reports $212.9M cash, runway through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $9M to Mabworks; up to $30M development/regulatory milestones for first indication.","Up to $832M commercial milestones across all products; tiered low-to mid-single-digit royalties.","Preliminary cash $212.9M and ~67.3M shares outstanding as of Dec 31, 2024.","Existing cash expected to fund operations, including budoprutug and CLYM116, through 2027.","Exclusive rights to MIL116 (CLYM116) outside China; non-exclusive rights for global trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194356,"accession_number":"0000950170-24-125336","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.","Cash $217.9M as of Sep 30, 2024; expected to fund operations through 2027.","FDA cleared IND for budoprutug in SLE; Phase 1b trial planned H1 2025.","Appointed Doug Williams as Chair of Board; Gary Hao as VP of CMC.","Phase 1b pMN data showed 60% complete remission; Phase 2 ITP trial planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194355,"accession_number":"0001193125-24-237196","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.","Phase 1b pMN: 3/5 patients achieved complete remission; rapid B-cell depletion and anti-PLA2R reductions.","Plans to initiate Phase 1b SLE trial and Phase 2 ITP trial in first half 2025, subject to regulatory clearance.","Subcutaneous formulation advancing; non-clinical data expected first half 2025.","Full pMN Phase 1b data to be presented at ASN Kidney Week on Oct 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194354,"accession_number":"0001193125-24-231167","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Eliem Therapeutics renames to Climb Bio, ticker changes to CLYM on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Eliem Therapeutics, Inc. to Climb Bio, Inc. effective October 2, 2024.","New trading symbol CLYM on Nasdaq Global Market starts October 3, 2024.","CUSIP number for common stock remains unchanged; stockholder rights unaffected.","Certificate of incorporation amended solely for name; bylaws conformed to new name."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210694,"accession_number":"0001193125-24-207854","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eliem Therapeutics CSO departs, CFO role changed, Executive Chairman resigns amid strategic pivot","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Valerie Morisset, EVP R&D and CSO, separated August 23; settlement provides 18 months base salary, pro rata bonus, accelerated equity vesting.","Company shifts focus to autoimmune-driven inflammatory diseases (budoprutug) and ceases UK operations.","Brett Kaplan appointed principal financial officer after Andrew Levin resigns as Executive Chairman; Levin remains Chairman.","Levin continues as director and Chairman of Board; Kaplan's COO role unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210693,"accession_number":"0001193125-24-206655","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eliem Therapeutics appoints Brett Kaplan as COO with equity grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Kaplan, M.D., appointed Chief Operating Officer effective August 26, 2024.","Base salary of $500,000/year; eligible for annual bonus up to 45% of base salary.","Granted option to purchase 465,000 shares and 77,500 RSUs under 2021 Equity Incentive Plan.","Option vests 25% at one year then monthly over 3 years; RSUs vest 25% annually over 4 years.","Severance: 9 months salary (non-CIC) or 12 months plus target bonus (CIC), plus COBRA and equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210692,"accession_number":"0000950170-24-096627","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eliem Therapeutics Q2 net loss $54.9M; completed Tenet Medicines acquisition and $120M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed acquisition of Tenet Medicines and concurrent $120M private placement in June 2024.","Cash and equivalents $223.1M as of June 30, expected to fund operations into 2027.","Net loss of $54.9M for Q2 2024 vs $5.2M in Q2 2023, largely due to $51.7M acquired IP R&D expense.","Lead product budoprutug (anti-CD19) targets autoimmune diseases including lupus and immune thrombocytopenia.","Appointed Aoife Brennan as CEO and Jan Hillson as Senior Clinical Advisor; added to Russell 2000 index."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229066,"accession_number":"0001193125-24-170599","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Eliem closes acquisition of Tenet Medicines, gains TNT119 autoimmune drug, raises $120M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Tenet closed June 27; 5,560,047 Eliem shares issued to Tenet equityholders.","PIPE of 31,238,282 shares raised ~$120M gross; proceeds to fund TNT119 development.","Lead asset TNT119 (budoprutug) licensed from Acelyrin; up to $157.5M in milestone payments plus royalties.","New CEO Aoife Brennan appointed effective close; Stephen Thomas joins board and as consultant.","Tenet also assumed CRH license with up to £106.8M milestones and ProBioGen cell line agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229065,"accession_number":"0001193125-24-169077","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Shareholders approve Eliem-Tenet merger; closing expected June 27, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share Issuance Proposal passed: 26,311,239 for, 3,253 against; disinterested approval 12,655,083 for.","Directors Andrew Levin and Liam Ratcliffe elected to board until 2027.","PricewaterhouseCoopers ratified as independent auditor for FY2024.","Acquisition of Tenet Medicines and concurrent PIPE expected to close on or about June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229064,"accession_number":"0001193125-24-159994","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Eliem appoints Aoife Brennan as CEO and director, effective upon Tenet merger close","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aoife Brennan appointed President and CEO, base salary $650K/yr, annual bonus target 55%.","Equity grant: incentive option for 550K shares and 275K RSUs, vesting over 4 years.","Stephen Thomas (Tenet CEO) appointed to board, expected to serve as consultant post-merger.","Andrew Levin to step down as principal executive officer but remain principal financial officer.","All appointments effective upon closing of Tenet acquisition; meeting on June 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229063,"accession_number":"0001193125-24-092520","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Eliem to acquire Tenet Medicines in stock deal; raises $120M PIPE at $3.84/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Eliem (ELYM) acquires Tenet via merger; Tenet holders get 15.4% of combined co. stock.","PIPE raises $120M from accredited investors at $3.84/share; closes after merger.","Stephen Thomas (Tenet CEO) to become interim CEO; William Bonificio interim CBO.","Combined board expands to 7 members: 5 current Eliem directors, Thomas, and 1 Tenet designee.","Deal requires disinterested stockholder vote; termination fee of $1M payable under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247670,"accession_number":"0001193125-24-070333","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eliem receives non-binding term sheet to acquire biotech Tango for $20M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["RA Capital owns ~47.5% of Eliem and majority of Tango; special committee oversees strategic review.","Eliem valued at $110M, Tango at $20M; post-deal Tango holders get 15.4% of combined entity.","Concurrent PIPE financing to be sized by parties; RA Capital expected to participate.","Deal requires approval of majority of Eliem shares not held by RA Capital (non-waivable condition).","Non-binding; subject to due diligence, definitive agreement, and independent committee clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282323,"accession_number":"0001193125-23-190074","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Eliem halts Kv7 program, explores strategic alternatives including sale or merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Halts further development of Kv7 program; shifts focus to maximizing shareholder value.","Engages Leerink Partners as strategic advisor to explore acquisition, merger, or business combination.","Reports preliminary unaudited cash, cash equivalents, and marketable securities of ~$102.6M as of June 30, 2023.","No timetable set for strategic review; no assurance any transaction will occur."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301492,"accession_number":"0001193125-23-149424","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eliem Therapeutics announces 2023 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Simon Tate elected as Class II director with 21,144,596 votes for, 555,897 withheld, 891,450 broker non-votes.","Ratification of PricewaterhouseCoopers as auditor: 22,574,271 for, 3,897 against, 13,775 abstentions.","Annual meeting held virtually on May 18, 2023; two proposals voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301491,"accession_number":"0000950170-23-021244","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Eliem Therapeutics Q1 net loss $22.3M; cash $109.4M funds operations into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.3M for Q1 2023 vs $13.2M in Q1 2022; includes $15.8M restructuring costs.","Cash, cash equivalents and marketable securities $109.4M as of March 31, 2023.","Presented initial preclinical data for lead Kv7 candidate ETX-123; IND-enabling studies initiated.","Phase 1 clinical studies for ETX-123 planned to start in first half of 2024.","R&D expenses $5.7M, G&A expenses $17.7M (includes $14.0M restructuring costs)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321290,"accession_number":"0001193125-23-072646","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eliem Therapeutics Announces CFO Resignation and Appoints New Principal Financial and Accounting Officers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Lavelle resigned as EVP, COO, and CFO effective March 10, 2023.","Andrew Levin, Executive Chairman, appointed as principal financial officer (in addition to principal executive officer).","Emily Pimblett, Chief Accounting Officer, appointed as principal accounting officer.","Levin is a co-founder and managing director at RA Capital Management; Pimblett previously held roles at DomainTools and Avvo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321289,"accession_number":"0000950170-23-006282","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eliem restructures, pauses ETX-155, focuses on Kv7 program, extends cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate reorganization: pause ETX-155 (GABA A PAM) development, focus on Kv7 program lead ETX-123; workforce reduction ~55% in H1 2023.","Andrew Levin appointed Executive Chairman after CEO Bob Azelby departure; Dr. Valerie Morisset continues as EVP R&D and CSO.","Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.","Net loss for FY2022: $45.2M ($7.8M Q4), compared to $47.5M in FY2021; R&D expenses $26.2M, G&A $18.9M.","IND-enabling studies for ETX-123 initiated; Phase 1 studies planned for H1 2024; preclinical data at March 2023 symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321288,"accession_number":"0001193125-23-036503","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Eliem Therapeutics pauses ETX-155, cuts workforce 55%, CEO and CFO depart; cash $123.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pauses development of ETX-155 (Phase 2-ready for MDD) to focus on preclinical Kv7.2/3 program (ETX-123).","Workforce reduced by ~55% in first half 2023; estimated $17.1M restructuring charges ($7.3M cash).","CEO Robert Azelby resigns; Andrew Levin appointed Executive Chairman; CFO Erin Lavelle and GC Jim Bucher also departing.","Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.","Plans to commence Phase 1 trial for ETX-123 in first half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321287,"accession_number":"0001193125-23-014221","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Leone Patterson resigns from Eliem Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leone Patterson resigned from the Board effective Jan 19, 2023, citing no disagreement on operations.","Board size reduced from 7 to 6 directors.","Audit Committee reconstituted: Adam Rosenberg (Chair), Simon Tate, Judith Dunn.","Nominating and Corp Gov Committee: Simon Tate (Chair), Liam Ratcliffe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339398,"accession_number":"0001193125-22-309122","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eliem Therapeutics sets 2023 base salaries and bonuses for named executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Azelby: $438,750 2022 bonus; 2023 base $702,000, 65% target bonus (company goals only).","COO/CFO Lavelle: $209,588 2022 bonus; 2023 base $484,380, 45% target bonus.","CSO Morisset: £145,467 2022 bonus; 2023 base £336,190, 45% target bonus.","2023 company performance goals to be set later by Board; individual goals subjective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339397,"accession_number":"0000950170-22-024621","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.","Cash and marketable securities $129.6M as of Sep 30, 2022; cash runway expected to fund operations into 2025.","ETX-155 Phase 2a MDD trial to initiate in Q1 2023 with 60-mg dose; topline data expected H2 2024.","Kv7.2/3 program: IND-enabling safety studies for two pre-candidates expected Q1 2023; Phase 1 studies planned H1 2024.","Phase 1 PK trial completed; selected 60-mg dose over 75-mg due to marginal additional benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339396,"accession_number":"0001193125-22-257937","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-10-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.","ETX-155 60mg single-dose exposures in Phase 1 PK trial consistent with prior trials; low PSE exposures within previously reported variability.","Company to evaluate 75mg repeat dose in ongoing Phase 1 PK trial; final results expected Q4 2022.","Phase 2a MDD trial to initiate Q1 2023; topline data mid-2024. PSE trial not reinitiated; FOS development continues.","Kv7 program: two pre-candidates scaling up for IND-enabling studies Q1 2023; Phase 1 studies H1 2024. GAD program discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356769,"accession_number":"0000950170-22-017192","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eliem Therapeutics Q2 net loss $14.6M; discontinues ETX-810 Phase 2a after failure","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M for Q2 2022 vs $8.7M in Q2 2021; cash, equivalents, securities $134.7M.","ETX-810 discontinued after failing primary endpoint in lumbosacral radicular pain Phase 2a.","Initiated Phase 1 PK trial for ETX-155; results expected Q4 2022; Phase 2a MDD planned Q1 2023.","Cash runway now expected to fund operations into 2025 due to ETX-810 discontinuation.","R&D expenses $8.8M (up from $5.8M YoY); G&A $4.9M (up from $2.9M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356768,"accession_number":"0001193125-22-196384","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eliem delays ETX-155 Phase 2a MDD trial to Q1 2023 after lower exposure in PSE trial; CMC issue identified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lower-than-expected ETX-155 exposure in Phase 1b photosensitive epilepsy trial attributed to CMC batch inconsistencies.","Phase 1 PK trial in healthy subjects expected Q4 2022 to determine dose for Phase 2a MDD trial.","Phase 2a MDD trial now expected to start Q1 2023 with topline data in mid-2024.","Phase 2a PMD trial postponed to preserve investment flexibility; PSE trial paused pending PK data.","Cash ($149.9M as of March 2022) expected to fund operations and pipeline catalysts through mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375228,"accession_number":"0001193125-22-158523","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eliem Therapeutics shareholders elect three directors, ratify PwC as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Azelby, Judith Dunn, Adam Rosenberg elected Class I directors with >20M votes for each.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2022 with 24,137,141 votes for, 4,086 against.","Broker non-votes: 1,346,296 on director elections; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375227,"accession_number":"0000950170-22-009922","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.","ETX-810 Phase 2a in diabetic peripheral neuropathic pain failed primary endpoint; LSRP trial fully enrolled, topline data Q3 2022.","ETX-155 Phase 1b photosensitive epilepsy interim results inconclusive due to lower exposure; Phase 2a MDD/PMD enrollment delayed pending root cause.","Preclinical Kv7.2/3 channel opener on track for IND-enabling studies in 2022; early anxiolytic program for GAD continues."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":636164431.8210701,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-16T23:59:59+00:00|375227"}